KLRC1 and B-cell chronic lymphocytic leukemia: Pre-treatment of CLL cells with selinexor (500 nM) significantly (p < 0.01) increased NKG2A + NK cell degranulation against CLL cells in combination with both rituximab and obinutuzumab in all donors assessed (n = 8) (Fig. 5A, B).